Who Investigates Opioid Fraud
Opioid fraud is not investigated by one agency. It is investigated by several agencies simultaneously, with overlapping jurisdiction, shared databases, and coordinated enforcement strategies that most practitioners do not fully appreciate until they find themselves within the scope of all of them at once.
The fragmentation of enforcement authority across multiple federal and state agencies is not accidental. It reflects the multidimensional character of opioid fraud itself, which simultaneously implicates controlled substance law, federal healthcare program integrity, tax law, financial regulation, and state medical licensing standards. Each dimension of the offense has a corresponding enforcement body with independent authority to investigate it, and those bodies share information, coordinate their activities, and refer matters to each other in ways that mean a single prescribing practice can find itself the subject of concurrent investigations by agencies the practitioner did not know were looking.
The Drug Enforcement Administration
The DEA is the lead federal agency for controlled substance diversion investigations. Its Diversion Control Division conducts regulatory inspections of DEA registrants, investigates controlled substance prescribing and dispensing outside the usual course of professional practice, and generates criminal referrals to United States Attorney’s offices when the evidence supports prosecution. The DEA’s special agent component conducts the criminal investigations that precede indictment, working with federal prosecutors to build cases against practitioners, pharmacies, and distributors whose conduct the diversion investigation identified.
The DEA’s Tactical Diversion Squads, operating in field divisions across the country, concentrate investigative resources on geographic areas with the highest rates of controlled substance diversion. The squads include DEA special agents and diversion investigators, federal prosecutors, and in some cases state and local law enforcement personnel who bring state enforcement authority to complement the federal investigation. The squad model produces investigations that can result in simultaneous federal and state charges arising from the same conduct.
The Department of Justice and United States Attorney’s Offices
Federal criminal prosecution of opioid fraud is the responsibility of the United States Attorney’s office in the district where the conduct occurred. Many districts have established dedicated healthcare fraud units or narcotics units that concentrate prosecutorial expertise in opioid-related cases. The DOJ’s Criminal Division, through its Fraud Section and Narcotic and Dangerous Drug Section, provides support to district-level prosecutions in complex multi-district or nationally significant cases.
The DOJ also coordinates the Health Care Fraud Prevention and Enforcement Action Team, known as HEAT, which operates joint task forces with the Department of Health and Human Services’ Office of Inspector General to address healthcare fraud including opioid prescribing fraud. HEAT task forces have conducted coordinated nationwide enforcement actions that charged hundreds of defendants simultaneously, demonstrating the scale of coordinated federal opioid enforcement.
The Office of Inspector General
The OIG of the Department of Health and Human Services investigates fraud, waste, and abuse in federal healthcare programs including Medicare and Medicaid. When opioid prescribing generates false claims to those programs, the OIG’s investigative authority is engaged alongside the DEA’s controlled substance authority. The OIG has independent subpoena authority, can conduct civil investigations in parallel with criminal investigations, and can impose civil monetary penalties and Medicare and Medicaid exclusion independently of the criminal proceeding.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196OIG special agents and audit staff review billing data from Medicare and Medicaid claims to identify prescribing patterns inconsistent with legitimate medical practice. The billing data provides a different but complementary view of prescribing conduct compared to the PDMP data the DEA uses, and the two agencies’ analysis of the same practitioner’s conduct from different data sources produces an investigation with greater evidentiary depth than either agency could achieve independently.
State Agencies
State medical licensing boards, state pharmacy boards, and state attorneys general each have independent authority over the practitioners and entities within their regulatory jurisdiction. State medical boards investigate complaints about physician conduct, including opioid prescribing practices, and may impose conditions on, suspend, or revoke a physician’s state medical license. State pharmacy boards exercise parallel authority over pharmacists and pharmacy permits. State attorneys general may bring civil or criminal actions under state consumer protection, public nuisance, or controlled substance statutes.
The coordination between state and federal agencies in opioid enforcement has intensified in the years since the crisis became a recognized public health emergency. State agencies routinely share PDMP data, licensing records, and investigative findings with the DEA and the OIG. Federal agencies refer matters to state boards when the evidence supports state licensing action even where it does not support federal criminal prosecution. The result is an enforcement network that can reach the same practitioner through multiple independent channels.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
The practitioner who is contacted by the DEA and who assumes that addressing the DEA inquiry will resolve all of their legal exposure has misunderstood the enforcement landscape. The DEA contact is one channel in a multi-channel investigation whose full scope may not become apparent until proceedings have been initiated in each forum simultaneously.
Financial Investigators and the IRS
When opioid fraud involves significant cash transactions, unreported income, or financial structuring, the Internal Revenue Service’s Criminal Investigation division and the Financial Crimes Enforcement Network may become involved in the investigation. A pill mill operation that generated substantial cash revenue and whose practitioners did not report that revenue as income has created tax evasion exposure alongside the controlled substance and healthcare fraud exposure. The IRS CI’s involvement in an opioid fraud investigation reflects the government’s comprehensive approach to financial accountability for practitioners whose conduct generated profits outside legitimate medical billing.
Understanding the full scope of the agencies that may be investigating the same conduct, and retaining counsel experienced in managing multi-agency investigations, is the foundation of an effective defense in opioid fraud matters. The investigation that appears to come from one direction may be coming from several simultaneously.
